Thomas Stephen Basil
SEC Form 4 insider trading activity
Thomas Stephen Basil has filed 3 SEC Form 4 filings (5 transaction rows) across 1 company, with disclosures dating back to 2026. 3 of those filings fall inside the rolling window. Most recent filing: Sep 17, 2026.
On the most recent filing, Thomas Stephen Basil is listed as Director at Climb Bio, Inc. Inside the rolling window, Thomas Stephen Basil reported no open-market purchases and 5 open-market sales totaling $2.2M in CLYM. The largest disclosed transaction in the window is a sale of 100,000 CLYM shares on Sep 15, 2026, worth $1.4M.
Companies traded
Other insiders at CLYM
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$2.2M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Thomas Stephen Basil made?
Thomas Stephen Basil has filed 3 SEC Form 4 filings (5 transaction rows) across 1 company since 2026.
Which companies does Thomas Stephen Basil trade?
Thomas Stephen Basil has filed SEC Form 4 disclosures for 1 company, including CLYM.
When was Thomas Stephen Basil's most recent SEC Form 4 filing?
Thomas Stephen Basil's most recent SEC Form 4 filing on Tracefour is dated Sep 17, 2026.
What is Thomas Stephen Basil's total buy and sell value in the current window?
Inside the rolling retention window, Thomas Stephen Basil bought $0 and sold $2.2M based on SEC Form 4 filings.
What was Thomas Stephen Basil's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 100,000 CLYM shares on 2026-09-15, worth $1.4M, per SEC Form 4 filings.